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Aim of the study: Neuroblastoma 
(NBL) is one of the most common ex-
tracranial tumours occurring in chil-
dren with N-Myc gene amplification, 
acknowledged as a marker of poor 
prognosis. We assessed the frequency 
of N-Myc amplification and its impact 
on NBL markers and on the treatment 
outcome.
Material and methods: Among 
160 children with NBL treated from 
1991 to 2015 in one centre 140 pa-
tients had known N-Myc gene status, 
and they were enrolled in the study. 
The analysed group was divided 
into two subgroups: with and with-
out N-Myc amplification (25 and 115 
children, respectively). Association of 
N-Myc amplification with stage of the 
disease, levels of biochemical param-
eters, overall survival (OS) and fail-
ure-free survival (FFS) were analysed. 
Results: The frequency of N-Myc am-
plification was 17.9%. Most children 
with N-Myc amplification (64%) were 
classified to stage 4 NBL. The levels of 
biochemical markers of NBL: ferritin, 
dopamine, NSE, and LDH were signifi-
cantly higher in the group with N-Myc 
amplification, whereas the levels of 
VMA and HVA were lower. OS and FFS 
were significantly lower in children 
with N-Myc amplification in compari-
son to children from the control group 
(OS 53% vs. 76%, p = 0.03; FFS 50% vs. 
72%, p = 0.03). The impact of N-Myc 
amplification on the treatment out-
come was significant in patients with 
stage 4 NBL and children under one 
year of age. 
Conclusions: N-Myc amplification is 
a crucial prognostic factor in neuro-
blastoma, which is associated with 
almost all features related with poor 
prognosis and a higher probability of 
unfavourable outcome. 
Key words: neuroblastoma, children, 
N-Myc gene amplification, treatment 
outcome.
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Introduction
Neuroblastoma (NBL) is the most commonly occurring extracranial malig-
nant solid cancer in children and comprises 8–10% of all tumours in children. 
Median age at diagnosis is 17 months [1]. Neuroblastoma arises from the 
neural crest, which usually gives rise to parts of sympathetic nervous system 
and adrenal glands. The primary tumour is usually located in the abdomen 
(retroperitoneal space) or posterior mediastinum, but it can be found in all 
parts of the body where embryonic cells of sympathetic nervous system 
occur. In Poland there are approximately 60–70 new cases of NBL annually 
[2]. Among all children’s deaths due to cancer, 15% die of neuroblastoma 
[3]. The characteristic neuroblastoma feature is the diversity of its course: 
both rapid metastasis and spontaneous regression with differentiation to 
benign tumours, e.g. ganglioneuroma, can be observed. The percentage 
of spontaneous regressions is one of the highest from all human cancers 
[4, 5]. Five-year overall survival has increased sharply from 52% (1975–1977) 
to 74% (1999–2005), but it is mainly because of better curability in the low-
risk group. For patients that are classified as high risk, the results of treat-
ment are still unsatisfying [6]. 
Age at diagnosis (better prognosis in children younger than 18 months) 
and stage of disease are important prognostic factors influencing the treat-
ment [6, 7]. Neuroblastoma affects boys more often than it does girls [8–10].
The most significant genetic marker of poor prognosis is N-Myc oncogene 
amplification (over four-fold increase of the N-Myc signal number in relation 
to the number of reference signals on chromosomes 2) [11]. Therapy should 
be stratified on the basis of the presence of N-Myc amplification [12, 13]. 
N-Myc belongs to the proto-oncogene family that products particles taking 
part in processes such as cell growth, differentiation, and apoptosis [14]. Dis-
turbance in the regulation of their courses may lead to excessive and unre-
stricted cell proliferation, which is widely observed in cancers [15]. There are 
some other genetic lesions coexisting with N-Myc, which may have an influ-
ence on prognosis, such as DDX1 amplification, but their clinical meaning is 
still unclear [16]. Crucial predictive factors are also deletion of the long arm 
of chromosome 11 and deletion of the short arm of chromosome 1, which 
both, independently, correlate with poor prognosis [17]. Gain of the long arm 
of chromosome 17 is another prognostic factor [18]. Distinct factors that cor-
relate with good prognosis are triploidy of tumour cells (as opposed to dip-
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loidy and tetraploidy) and high expression of neurotrophin 
receptor TrkA [19, 20]. In the case of lack of N-Myc ampli-
fication, currently the presence or absence of segmental 
chromosomal aberrations in NBL tumour cells is the most 
important biological prognostic factor [21]. 
The aim of the study was a retrospective analysis of the 
impact of N-Myc amplification on disease course in neuro-
blastoma patients.
Material and methods
From the group of 160 children with NBL, who were 
treated from 1991 to 2015 in the Department of Paediatric 
Oncology and Haematology, University Children’s Hospital 
of Krakow in Poland, the investigation focused on 140 chil-
dren (87.5%) whose N-Myc amplification status had been 
verified at the onset of disease. Observation was finished 
in December 2017. Before 2002 intensity of the treatment 
was based mainly on disease advance and age. N-Myc 
gene status did not influence the therapy. There was no 
uniform protocol for infants, they were treated according 
to data available in publications. Therapy for older chil-
dren was based on Japanese protocols (Tokyo). From 2002 
European protocols were introduced in Poland. N-Myc 
gene amplification become an important risk factor. Stan-
dard-risk infants were treated according to Infant-NBL-99. 
From 2006 high-risk infants (stage 2–4 with N-Myc gene 
amplification) were treated according to the protocol for 
high-risk patients older than one year (HR-NBL-1/ESIOP) 
comprising combined chemotherapy, stem cell mobili-
sation and apheresis, surgery, mega-dose chemotherapy 
with autotransplantation, radiotherapy, and the treatment 
of residual disease with retinoid acid, and from 2012 also 
with immunotherapy. Vanillylmandelic acid (VMA) and 
homovanillic acid (HVA) levels were tested in 24-hour 
urine collection. Because the analysed group was not nu-
merous and very diversified regarding the treatment, no 
analysis comprising methods of therapy was performed. 
Patients were between eight days and 14.4 (median 
1.6 years) years old at diagnosis. Diagnosis was made on 
the basis of primary tumour histopathological examina-
tion or the presence of cancer cells in the bone marrow and 
increased catecholamines and/or their metabolites’ levels 
in urine according to international criteria. The following 
examinations were done in all patients: radiological imag-
ing, whole-body scintigraphy with MIBG or bone scintig-
raphy with technetium (in MIBG non-avid patients), and 
biochemical tests and genetic examination of the tumour. 
N-Myc amplification tests were performed on touch prints 
prepared immediately after tumour removal or, when it 
was impossible, on paraffin-embedded tumour tissue by 
fluorescence in situ hybridisation using two-colour mo-
lecular probe N-MYC (MYCN) Amplification (Cytocell Ltd., 
Cambridge). Stage of disease was established on the ba-
sis of the International Neuroblastoma Staging System. 
Clinical data was reported on the basis of medical docu-
mentation. The kind and intensity of therapy depended on 
children’s age, stage, and biological features of disease [2].
The study was carried out in two groups. The first group 
was represented by children with NBL with N-Myc ampli-
fication (analysed group, n = 25), the second group was 
represented by children with NBL (control group, n = 115) 
without N-Myc amplification. Comparative analyses were 
performed for the following parameters: age at diagnosis, 
sex, stage of disease, and initial levels of: ferritin, dopa-
mine, VMA, HVA, neurospecific enolase (NSE), and lactate 
dehydrogenase (LDH). Treatment results were also evalu-
ated. 
Statistical calculations were carried out with Statistica® 
software package. One-way analyses were conducted us-
ing c2 test. Nonparametric Kolmogorov-Smirnov test was 
used to compare biochemical parameters in two groups 
of patients with and without N-Myc amplification. Overall 
survival (OS, time from diagnosis to death or last obser-
vation) and failure-free survival (FFS, time from diagnosis 
to relapse or progression of disease before obtaining com-
plete remission, or last observation) were estimated using 
Kaplan-Meier method. Differences between curves were 
analysed with Log-Rank test. Statistical significance was 
set at p = 0.05. 
Results
Among 140 NBL evaluated patients, we found 25 (17.9%) 
children with presence of N-Myc gene amplification. 
N-Myc amplification was not found in any of the nine chil-
dren in stage 1. The amplification was present in: 1 (6.3%), 
6 (13.3%%), 2 (18.2%), and 16 (27.1%) patients, in stage 2, 
3, 4s, and 4 of disease, respectively. All children with N-Myc 
amplification had unfavourable histopathology evaluated 
according to International Neuroblastoma Pathology Clas-
sification [22]. 
The results of comparison of biochemical parameters in 
groups with and without N-Myc amplification are shown 
in Table 1. N-Myc amplification occurred with similar fre-
quency in boys and girls (18% in each group). Median age 
in both groups was comparable (1.98 years in the anal-
ysed group, 1.45 years in the control group). In the N-Myc 
amplification-positive group there were 18 (72%) children 
older than one year, and in the control group there were 
67 (58.3%) children older than one year. The difference 
was not statistically significant (p > 0.1). Among the chil-
dren with N-Myc amplification the most frequent NBL 
stage was 4 (64%), but compared to control group (37%) 
there was no statistical significance (p > 0.1). 
In the analysed patients, ferritin level at diagnosis of 
the disease was checked in 109 cases (77.9% of patients 
with known N-Myc status). In the group with N-Myc am-
plification (n = 21) the median ferritin concentration was 
higher than in the control group (n = 88), at 288.6 µg/l and 
132.6 µg/l, respectively. The difference was statistically sig-
nificant (p < 0.01). 
Dopamine level was initially checked in 103 cases (73.6% 
of patients with known N-Myc status). In the N-Myc ampli-
fication-positive group (n = 17) and control group (n = 86) 
median dopamine concentration was 12.726 µg/mg creat-
inine and 2.045 µg/mg creatinine, respectively. The differ-
ence was statistically significant (p < 0.025). NSE level was 
checked at diagnosis in 80 cases (57.1% of patients with 
specified N-Myc status). In the analysed group (n = 12) and 
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control group (n = 68), the median NSE concentration was 
418.2 ng/ml and 67.745 ng/ml, respectively. The difference 
was statistically significant (p < 0.01). LDH activity was ini-
tially checked in 125 cases (89.3% of patients with speci-
fied N-Myc status). In the group with amplification (n = 21) 
and without amplification (n = 104) median LDH activity 
was 3989 U/l and 1015.5 U/l, respectively. The difference 
was statistically significant (p < 0.01).
Vanillylmandelic acid level was initially checked in 115 
cases (82.1% of patients with specified N-Myc status). In 
the N-Myc amplification-positive group (n = 19) and control 
group (n = 96) median VMA concentration was 22.935 µg/mg 
creatinine and 68.626 µg/mg creatinine, respectively. The 
level of VMA in urine was considerably higher in the group 
without N-Myc amplification. The difference was statisti-
cally significant (p < 0.005). HVA level was checked at the 
onset of disease in 107 cases (76.4% of patients with spec-
ified N-Myc status). In the analysed group (n = 18) and con-
trol group (n = 89) median was 61.525 µg/mg creatinine 
and 69.438 µg/mg creatinine, respectively. The difference 
was not statistically significant (p > 0.1).
Because the main aim of the study was the evaluation 
of the impact of N-Myc amplification on disease course 
in patients with NBL, we decided to exclude from the OS 
assessment the patients whose death was not caused by 
NBL. Treatment complications were the reason of death in 
one patient from the N-Myc amplification-positive group 
and five children from the control group. Deaths because 
of NBL occurred in 11 (44.0%) out of 25 patients with N-Myc 
amplification and 27 (23.5%) out of 115 patients in the con-
trol group. The difference was not statistically significant 
(p > 0.1). Five-year OS for patients with and without N-Myc 
amplification was 58 ±10% and 79 ±4% (Fig. 1), respective-
ly. The difference was statistically significant (p = 0.03).
Table 1. Patient characteristic
Parameters Number of patients (%) p-value
With N-Myc 
amplification
n = 25
Without N-Myc 
amplification
n = 115
Sex Boys 14 (56.0) 65 (56.5)
> 0.11Girls 11 (44.0) 50 (43.5)
Age of diagnosis Range (months) 2.4–134.4 0.3–172.4
Median (years) 1.98 1.45 > 0.12
Number of patients > 1 year of age 18 (72.0) 67 (58.3)
> 0.11Number of patients ≤ 1 year of age 7 (18.0) 48 (41.7)
Stage of NBL 1 0 (0.0) 9 (7.8)
2 1 (4.0) 15 (13.0)
3 6 (24.0) 39 (33.9) > 0.11
4 16 (64.0) 43 (37.4) > 0.11
4s 2 (8.0) 9 (7.8)
Ferritin (µg/l) Number (%) of evaluated patients 21 (77.9) 88 (76.5)
< 0.012Range 31.8–1515 2.9–1728.7
Median 288.6 132.6
Dopamine (µg/mg 
creatinine)
Number (%) of evaluated patients 17 (68.0) 86 (74.8)
< 0.0252Range 0.724–601 0.21–4816
Median 12.726 2.045
Neurospecific 
enolase
(ng/ml)
Number (%) of evaluated patients 12 (48.0) 68 (59.0)
< 0.012Range 66.92–3581 12.03–2550
Median 418.2 67.745
Lactate 
dehydrogenase
(U/l)
Number (%) of evaluated patients 21 (84) 104 (90.4)
< 0.012
Range 207–22500 209.7–11364
Median 3989 1015.5
Vanillylmandelic 
acid (µg/mg 
creatinine)
Number (%) of evaluated patients 19 (76.0) 96 (83.5)
< 0.0052Range 0–488.7 0–1841.57
Median 22.935 68.626
Homovanillic acid
(µg/mg creatinine)
Number (%) of evaluated patients 18 (72.0) 89 (77.4)
> 0.12Range 8.93–589.7 3.9–1394.454
Median 61.525 69.438
1c2 test; 2Kolmogorov-Smirnov test
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Therapy failure defined as progression or relapse oc-
curred in 12 (48.0%) out of 25 patients with amplification 
of N-Myc and 33 (28.7%) out of 115 patients in the con-
trol group. The difference was not statistically significant 
(p > 0.1). Five-year FFS for patients with and without N-Myc 
amplification was 50 ±10% and 72 ±4%, respectively (Fig. 2). 
The difference was statistically significant (p = 0.03).
In a subgroup of 81 patients in stage 1, 2, 3, and 4s of 
NBL there were nine patients with N-Myc amplification 
and 72 without amplification. Five-year OS for patients 
with and without N-Myc amplification was 89 ±10% and 
91 ±3%, respectively. Five-year FFS for patients with and 
without N-Myc amplification was 89 ±10% and 89 ±4%, 
respectively. There was no significant difference in OS and 
FFS between patients with and without N-Myc amplifica-
tion in this group (p > 0.1).
In a subgroup of 59 patients with stage 4 NBL there 
were 16 patients with N-Myc amplification and 43 with-
out N-Myc amplification. Five-year OS was 38 ±13% and 
55 ±8% in patients with and without N-Myc amplifica-
tion, respectively (Fig. 3). Although the difference was not 
statistically significant (p = 0.096), some trend could be 
Fig. 1. Overall survival (OS) in all analysed children with neuroblas-
toma depending on N-Myc amplification
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Fig. 2. Failure-free survival (FFS) in all analysed children with neuro-
blastoma depending on N-Myc amplification
Fig. 4. Overall survival (OS) in children with neuroblastoma ≤ 1 year 
old at diagnosis depending on N-Myc amplification
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Fig. 3. Overall survival (OS) in patients with neuroblastoma stage 
4 depending on N-Myc amplification
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Fig. 5. Failure-free survival (FFS) in children with neuroblastoma 
≤ 1 year old at diagnosis depending on N-Myc amplification
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observed towards OS improvement in the non-amplified 
group. The difference in FFS between two groups was not 
statistically significant (p > 0.1).
In a subgroup of 55 patients who were younger than 
one year old (≤ 12 months) at diagnosis there were seven 
patients with N-Myc amplification and 45 without N-Myc 
amplification. Five-year OS was 71 ±17% and 98 ±2% (Fig. 4) 
for patients with and without N-Myc amplification, re-
spectively. The difference was statistically significant 
(p = 0.004). Five-year FFS was 71 ±17% and 96 ±3%, respec-
tively for patients with and without N-Myc amplification 
(Fig. 5). The difference was statistically significant (p = 0.02).
In a subgroup of 85 patients who were older than one 
year (18 children with and 67 children without N-Myc am-
plification) five-year OS was 51 ±13% and 64 ±6% for these 
two subgroups, respectively. The difference was not sta-
tistically significant (p > 0.1). No significant difference in 
five-year FFS was found (40 ±12% vs. 55 ±6%, respectively, 
p > 0.1). 
We compared OS and FFS in children with N-Myc ampli-
fication depending on age at diagnosis. Among 25 patients 
with N-Myc amplification there were 18 over one year old 
and seven who were below one year old at diagnosis. No 
significant difference in five-year OS was found (51 ±13% 
vs. 71 ±18%, respectively, p = 0.4). Similarly, there was no 
significant difference in five-year FFS (40 ±12% vs. 71 ±17%, 
respectively, p = 0.3). 
Discussion
Amplification of N-Myc oncogene is a known marker 
of poor prognosis in neuroblastoma. [9, 10]. In our study 
N-Myc status was known in 87.5% of all children diag-
nosed with NBL in our centre from 1992 to 2015. In 12.5% 
of patients there were no data concerning N-Myc, or ex-
amination of the marker was not done. N-Myc amplifica-
tion occurred slightly less often (17.9%) than was reported 
by other authors (25%) [23]. It was also found out that 
children with N-Myc amplification were more often (64%) 
classified to stage 4 than the patients without amplifica-
tion (37%), which relates to other studies (Table 1) [24]. 
Moreover, no N-Myc amplification was found in children 
with stage 1 NBL. It is worth noting that tumours in all chil-
dren with N-Myc amplification had unfavourable histopa-
thology, which is one of the crucial aspects when it comes 
to prognostic analysis [25]. 
High serum ferritin level without a corresponding in-
crease in tissue iron storage is observed in patients with 
neuroblastoma. Moreover, when the serum ferritin level 
normalises, the probability of remission increases [26]. It 
is interesting that in the study the differences between 
groups were statistically significant (the group with N-Myc 
amplification had significantly higher levels of ferritin). 
Elevated dopamine level in urine is associated with poor 
prognosis in neuroblastoma. It occurs especially in stages 
3 and 4 [27]. This biochemical parameter was also statis-
tically significantly increased in the group with N-Myc am-
plification. The levels of both NSE and LDH in serum are 
positively associated with worse prognosis in neuroblasto-
ma and are useful in the monitoring of treatment [28]. In 
our study both parameters were statistically significantly 
higher in the group of patients with N-Myc amplification 
in comparison with the group without amplification (Ta- 
ble 1). Elevated levels of VMA and HVA in urine are ob-
served in 68–95% patients diagnosed with neuroblastoma 
[29]. In our study both levels were lower in the group of 
children with N-Myc amplification, which can lead to the 
conclusion that it is the HVA/VMA ratio, not their absolute 
levels, that could be a predictive factor, as was discovered 
in previous examinations [30].
In analysis concerning treatment outcome we found 
that children without N-Myc amplification had significant-
ly higher probability of overall and failure-free survival. We 
analysed also subgroups of patients. The difference in the 
probability of OS and FFS was statistically significant only 
in patients younger than one year of age (Figs. 4 and 5). In 
older children N-Myc amplification did not influence sig-
nificantly the treatment outcome. Probably this is due to 
the high number of stage 4 tumours in this group. No sta-
tistically significant differences in OS and FFS depending 
on N-Myc status were found in children with NBL stage 1, 
2, 3, and 4s, but the number of patients with N-Myc ampli-
fication in this group was low (9/81, 11%). In patients with 
NBL stage 4 there was a trend for worse survival when 
N-Myc amplification was confirmed. However, the differ-
ence was not statistically significant (Fig. 3).
To sum up, we can state that N-Myc amplification is 
associated with elevated levels of biochemical markers 
corresponding to the disease activity and tumour mass. 
It also has a negative impact on life expectancy and is 
rightly perceived as one of the crucial factors that indicate 
bad prognosis in this cancer (Figs. 1 and 2). N-Myc status 
is obligatory checked in all patients with diagnosis of NBL. 
There is a need to continue the studies concerning N-Myc 
amplification. Further studies on larger groups of patients 
are needed. It is very important to confirm if it still is an 
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important prognostic factor in patients treated with more 
intensive protocols and if they should receive the same 
therapy as patients without N-Myc amplification. It is also 
evaluated whether it could be used for targeted therapy 
[31].
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